Adult T-cell leukemia-lymphoma (ATL) is an aggressive peripheral T-cell neoplasm with a poor prognosis, developing after long-term infection with human T-cell leukemia virus-1 (HTLV-1). Multiple factors (e.g., virus, host cells, epigenetic aberrations, and immune factors) have been implicated in the development of ATL, although the underlying mechanisms of leukemogenesis have not been fully elucidated. Despite recent progress in both chemotherapy and supportive care for hematological malignancies, the prognosis of ATL is still poor; overall survival at 3 years is only 24 ％. New strategies for the therapy and prophylaxis of ATL (e.g., vaccines and novel molecular target agents) are still required. This article reviews new strategy of ATL treatment targeted for HTLV-1-speciˆc cytotoxic T-lymphocytes (CTLs) and SIRT1, a longevity gene-encoded protein. HTLV-1-speciˆc CTLs play a critical role in the host immune response against HTLV-1. We have described here the decreased frequency and function of HTLV-1-speciˆc CD8＋ T cells in ATL patients and the e‹cient induction of the HTLV-1-speciˆc CTLs response in human leukocyte antigen-A 0201-transgenic mice by the HTLV-1/hepatitis B core chimeric particle and oligomannose-coated liposomes encapsulating HTLV-1 epitope without adjuvant, suggesting that the e‹cient antigen delivery system and CTL induction can be exploited to develop a prophylactic vaccine model against tumors and infectious diseases. Furthermore, our studies suggest that SIRT1, a longevity gene-encoded protein, is a crucial anti-apoptotic molecule in ATL cells, and that SIRT1 inhibitors may be useful therapeutic agents for leukemia, especially in patients with ATL. These studies targeted for antitumor immunity such as vaccine and SIRT1 may support the new prophylactic and therapeutic approach for ATL.
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INTRODUCTION
Adult T-cell leukemia/lymphoma (ATL), 1 3) an aggressive malignancy of mature peripheral T-lymphocytes, and human T-cell lymphotropic virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), 4 6) a chronic in‰ammatory disease, are two of the most important diseases associated with long term infection of HTLV-1, which has infected approximately 10 20 million people worldwide, particularly in Equatorial Africa, the Caribbean basin, South America, Melanesia, and southern Japan. 7) The lifetime risks of developing ATL and HAM/TSP are estimated to be approximately 2.5 ％ to 5％ and 0.3％ to 2％, respectively. The diŠerent patterns of clinical disease are thought to be linked to host immunogenetic factors. HTLV-1 is also associated with a variety of autoimmune disorders including T cell alveolitis, myopathy, uveitis, arthritis, and Sj äogren's syndrome, 8 11) although the precise relationship between these disorders and HTLV-1 infection remains unclear. Despite recent progress in both chemotherapy and supportive care for hematological malignancies, the median surviral time that followed the bes clinical results to date is approximately 13 months. 12 14) Therefore, new strategies for the therapy and prophylaxis of ATL (e.g., vaccines and novel molecular target agents) are still required.
Antigen-speciˆc cytotoxic T-lymphocytes (CTLs) induction is an attractive immunotherapeutic strategy against hematologic malignancies and other cancers. 15, 16) The di‹culty in inducing antigen-speciˆc CTLs in individual patients vitiates a more widespread use of adoptive T cell therapy. HTLV-1-speciˆc CTLs also play an important role in suppressing proliferation of HTLV-1-infected or transformed T-cells in vitro. 17, 18) Therefore, impaired host CTL function abrogates protection against accumulation of HTLV-1-transformed cells, and circumventing this hurdle may yield an eŠective immune strategy against leukemogenesis. 19, 20) SIRT1, a nicotinamide adenine dinucleotide (NAD ＋ )-dependent class III histone deacetylase, has been highlighted as a key regulator of lifespan extension by caloric restriction. 21) SIRT1 plays a crucial role in a variety of physiological processes, such as metabolism, apoptosis, and aging, due to its ability to deacetylate numerous substrates, such as histones, p53, and nuclear factor-kB (NF-kB). 22) NF-kB, which is a key mediator of the in‰ammatory response and is crucial for cell survival and proliferation, is activated in HTLV-1-infected cells by the transcriptional regulator Tax, an HTLV-1-encoded regulatory protein. 23) SIRT1 is of great signiˆcance with regard to both antiaging and tumorigenesis. 24) However, there have been no reports regarding SIRT1 regulation in ATL.
The onset of ATL after HTLV-1 infection appears to require a long latency period because the median age at diagnosis ranges from 40 to 60 years in most endemic regions where mother-child viral transmission had been previously common. 25) ATL is important with regard to studies of both the host immune system in chronic infection and virus-induced malignancy in humans. In this study, we investigated new strategy of ATL treatment targeted for HTLV-1-speciˆc CTLs and SIRT1.
DECREASED FREQUENCY AND FUNCTION OF HTLV-1-SPECIFIC CTL IN ATL
Frequency and Function of HTLV-1-speciˆc CD8＋ T-cell in HTLV-1-related Diseases HTLV-1-speciˆc CTL plays an important role in suppressing proliferation of HTLV-1-infected or transformed T cells in vitro 26, 27) and thus may prevent development of ATL. 28, 29) It is possible that CTL fails in only a fraction of HTLV-1 carriers with a speciˆc immunogenetic background. 30) Yashiki et al. identied HTLV-1 Tax epitopes recognized by human leukocyte antigen (HLA) class I molecules using peripheral blood mononuclear cell (PMBC) of asymptomatic HTLV-1 carriers (ACs) in vitro and reported that the frequencies of HLA alleles lacking epitope anchor motifs, HLA-A 26, HLA-B 4002, HL-B 4006, and HLA-B 4801, were higher in ATL patients than in ACs. Theseˆndings suggested that insu‹cient generation of CTL allowed outgrowth of HTLV-1-transformed cells in the host. 31) Theseˆndings suggested a key role of anti-HTLV-1 Tax CTL in prevention of ATL leukemogenesis. However, in vivo conditions of anti-HTLV-1 CTL before and after ATL development have yet to be determined.
To characterize anti-HTLV-1 CTL in ACs and ATL patients, we analyzed the frequency and diversity of HTLV-1-speciˆc CD8＋ T-cells in PBMC of ACs and ATL patients using 16 distinct epitopes of HTLV-1 Tax or Env/HLA tetramers, which was developed on the base of our identiˆed epitopes ( Table  1) , along with intracellular cytolytic eŠector molecules (interferon-gamma; IFN-g, perforin, and granzymeB). ACs possessed Tax11 19/HLA-A 0201-speciˆc tetramer＋ cells by 73％ and Tax301 309/ HLA-A 2402-speciˆc tetramer＋ cells by 94％ ( Table  1) . Some ACs recognized more than one epitope. In contrast, ATL recognized only Tax11 19 with HLA-A 0201 and Tax301 309 with HLA-A 2402 at frequencies of 33％ and 52％. Overall frequency of subjects possessing Tax-speciˆc CD8＋ T-cells was signiˆcantly lower in ATL than ACs (57％ vs. 96％, p＜ 0.001) whereas the diŠerence in Env-speciˆc CD8＋ T-cells was not statistically signiˆcant ( Table 2 ). There were also signiˆcant diŠerences in percentage of cells binding Tax11 19/HLA-A 0201 and Tax301 309/HLA-A 2402 tetramers between ACs and ATL (Fig. 1) . Contrarily, perforin and granzymeB expression in anti-HTLV-1 CD8＋ T-cells of ATL was signiˆcant lower than that of ACs. 32) Frequency of Taxspeciˆc CD8＋ T-cells in ACs were related with proviral load in HLA-A 0201. These results suggest that decreased frequency, diversity, and function of anti-HTLV-1 Tax CD8＋ T-cell clones may be one of the risks of ATL development. 32, 33) patients may be involved in progression from HTLV-1 carrier to ATL, and also contribute to the aggressiveness of this disease, which is refractory to treatment.
Central memory T-cells (T CM ) (CD45RA-/CCR7 ＋) deˆnes a pool of cells that have been activated, proliferated, and maintained the ability to migrate to lymphnodes where they can stimulate dendritic cells and B cells, but may be less e‹cient at mediating immediate eŠector functions. 34) EŠector memory T-cells Table 1) . CD8 ＋ cells binding to HTLV-1 Tax tetramers in CCs were signiˆcantly reduced compared with HAM/TSP patients (Fig. 1) . This study demonstrates the importance of CD8 ＋ T-cells recognizing HTLV-1 Envtetramers in HAM/TSP patients and CCs, thereby suggesting that the diversity, frequency and repertoire of HTLV-1 Env-speciˆc CD8 ＋ T-cell clones may be related to the hyperimmune response in HAM/TSP and CCs, although diŠerent immunological mechanisms may mediate the hyperimmunity in these conditions. 36, 37) Dysfunction of HTLV-1-speciˆc CD8＋ T-cell in ATL Patients via the PD-1/PD-L1 Pathway T cell receptor costimulatory pathways assist in regulating T cell activation and tolerance. 38 40) The B7-CD28 superfamily membership has been expanded to include costimulatory and inhibitory T cell receptors, including CD28 and programmed death-1 (PD-1). 39) Indeed, studies in PD-1-deˆcient mice have indicated that PD-1 serves as a negative regulator of immune responses. 41) The negative regulatory PD-1/programmed death-ligand 1 (PD-L1) pathway has been implicated in the induction of CTL exhaustion during chronic viral infection along with tumor escape from host immunity. Studies have also suggested that the PD-1/PD-L1 pathway in virus-speciˆc CD8＋ T cells may be operating in chronic HIV infection. 42) However, there is no report on PD-1 expression in tumor-associated antigen-speciˆc CTLs in humans. To determine whether the PD-1/PD-L1 pathway could be involved in the establishment of persistent HTLV-1 infections and immune evasion of ATL cells in patients, we examined PD-1/PD-L1 ex- pression on cells from ACs and ATL patients in comparison to cells from healthy donors (HDs). PD-1 expression on HTLV-1-speciˆc CTLs from ACs and ATL patients was dramatically elevated (Fig. 2A) . In addition, PD-1 expression was signiˆcantly higher on CD8＋ T-cells along with cytomegalovirus (CMV)-and Epstein-Barr virus (EBV)-speciˆc CTLs in ATL patients compared to ACs and HDs. Primary ATL cells in 21.7％ of ATL patients expressed PD-L1, while elevated expression was not observed in cells from ACs. 43) Finally, in functional studies we observed that an anti-PD-L1 antagonistic antibody upregulated HTLV-1-speciˆc CD8＋ T-cell response (Fig. 2B) . These observations suggest that the PD-1/ PD-L1 pathway plays a role in fostering persistent HTLV-1 infections, which may further ATL development and facilitate immune evasion by ATL cells. 43, 44) EFFICIENT INDUCTION OF HTLV-1-SPECIFIC CTL
Induction of HTLV-1-speciˆc CTL by Chimeric Particle without Adjuvant
Antigen-speciˆc CTL induction is an attractive immunotherapeutic strategy against hematologic malignancies and other cancers. 15, 16) The di‹culty in inducing antigen-speciˆc CTLs in individual patients vitiates a more widespread use of adoptive T cell therapy. Whereas free synthetic peptides have proven to be relatively poor immunogens, viral-like particles such as hepatitis B core (HBc) have been consistently shown to induce strong antibody responses and CTLs, even without adjuvant. 45, 46) The HBcAg, a potent immunogen eliciting strong humoral, T-helper and CTL responses and amenable to a variety of heterologous epitopes without adjuvant, 47) is a potentially eŠective carrier protein for T-cell mediated vaccine development. 48) In the present study, we fused HTLV-1 Tax11 19 peptide, recognized by HLA-A 0201-restricted HTLV-1-speciˆc CD8＋ T-cells with high frequency, 32) to the HBcAg to synthesize an HTLV-1/HBc chimeric particle (Fig. 3A, B) .
The immunization of HLA-A 0201 transgenic mice with the chimeric particle induced antigen-speciˆc IFN-g reaction, whereas immunization with epitope peptide only induced no reaction as assessed by enzyme-linked immunospot assay (Fig. 3C) . Immunization with the chimeric particle also induced HTLV-1-speciˆc CD8＋ T-cells in spleen and inguinal lymph nodes. 49) Furthermore, upon exposure of dendritic cells (DCs) from HLA-A 0201-transgenic mice to the chimeric particle, the expression of CD86, HLA-A02, Toll-like receptor 4 (TLR4) and Major Histocompatibility Complex (MHC) class II was increased (Fig. 4) . Additionally, our results show that HTLV-1-speciˆc CD8＋ T cells can be induced by peptide with HTLV-1/HBc particle from ATL patient, but not by peptide only and these HTLV-1- speciˆc CD8＋ T cells were able to lyse cells presenting the peptide. 49) It is also known that T helper epitopes in the HBc protein augment CTL development and enhance CD8＋ memory T-cell survival. Others have reported on the e‹cient processing of lymphocytic choriomeningitis virus-derived p33/HBc chimera via cross-presentation, although only weak CTL responses were induced in C57BL/6 mice. 48) Thus, while VLPs alone are ine‹cient at inducing CTL responses, they become very potent vaccines when combined with antigen presenting cell (APC) activating substances like anti-CD40 mAbs or nonmethylated CG motif-rich DNA (CpGs). These results suggest that HTLV-1/HBc chimeric particle is capable of inducing strong cellular immune responses without adjuvants via eŠective maturation of DCs and is potentially useful as an eŠective carrier for therapeutic vaccines in tumors, or in infectious diseases by substituting the epitope peptide. 49, 50) Oligomannose-coated Liposomes E‹ciently Induce HTLV-1-speciˆc CTL Oligomannose-coated liposomes (OMLs) can be incorporated into F4/80-positive macrophages or intraperitoneal CD11b-positive DCs resulting in the induction of a protective response following injection into the peritoneal cavity. 51, 52) OMLs may also activate peritoneal macrophages to upregulate the expression of costimulatory molecules and preferentially secrete IL-12, which would result in the activation of both CD4-positive and CD8-positive T cells. 53) Furthermore, OMLs employed in eŠective antigen-delivery could induce both Th subsets and CTL against ovalbumin antigens encapsulated in the liposomes. 54) OMLs using human monocytes/macrophages as a cellular vehicle have the potential to target peritoneal micrometastasis in the omentum of gastric cancer patients. 55) Therefore, OMLs can also be used as an eŠective antigen delivery system for cancer immunotherapy activating both CTL and Th subsets. 56, 57) Here, we examined the e‹cient induction of HTLV-1-speciˆc CD8＋ T cell response by OMLs encapsulating the HLA-A 0201-restricted HTLV-1 Taxepitope (OML/Tax).
Immunization of HLA-A 0201 transgenic mice with OML/Tax induced an HTLV-1-speciˆc IFN-g reaction, whereas immunization with epitope peptide alone induced no reaction (Fig. 5A) . Upon exposure of DCs to OML/Tax, the levels of CD86, MHC class I, HLA-A02 and MHC class II expression were increased. 58) In addition, our results showed that HTLV-1-speciˆc CD8＋ T cells can be e‹ciently induced by OML/Tax from HTLV-1 carriers compared with epitope peptide alone (Fig. 5B) , and these HTLV-1-speciˆc CD8＋ T cells were able to lyse cells presenting the peptide. These results were explained by the Th1-skewing of the cytokine proˆles due to the advantage of OML-mediated immunization. Mizuuchi et al. have recently reported the induction of CTLs speciˆc to the HLA-A24-restricted epitopes of Survivin2B by MLPC with OML-coated survivin2B peptide and those of human papillomavirus type16 E6 and E7 by MLC with OML-coated papillomavirus DNA (Mizuuchi et al. unpublished data). A previous study also showed that OMLs were preferentially incorporated into macrophages. 52) As the macrophage mannose receptor (CD206) is mainly expressed on macrophages, 59 ) the action of OMLs is thought to be caused by their facilitation of antigen delivery to macrophages as a result of interaction between CD206 and oligomannose exposed on the liposomes. In addition, a recent study showed that speciˆc ICAM-3 grabbing nonintegrin-related 1 and complement receptor type 3 played a crucial role in the uptake of OMLs by macrophages. 53) Uptake of the HTLV-1 antigen-encapsulating OMLs by macrophages would have been an initial key event in the induction of the antigen-speciˆc Th1 immune response. These results suggest that OML/Tax is capable of inducing antigen-speciˆc cellular immune responses without adjuvants and may be useful as an eŠective vaccine carrier for prophylaxis in tumors and infectious diseases by substituting the epitope peptide. 58) NEW STRATEGY OF ATL TREATMENT TAR-GETED FOR SIRT1
SIRT1, an NAD ＋ -dependent histone/protein deacetylase, plays a crucial role in various physiological processes, such as aging, metabolism, neurogenesis and apoptosis, due to its ability to deacetylate numerous substrates, such as histone and NF-kB, 22) which is implicated as an exacerbation factor in ATL. In this study, we set out to assess how SIRT1 is expressed and the action of a SIRT1 inhibitor in primary ATL cells and leukemic cell lines.
SIRT1 expression in ATL patients was signiˆcantly higher than that in healthy controls, especially in the acute type (under submission). 60) Sirtinol, a SIRT1 inhibitor, induced signiˆcant growth inhibition or apoptosis in cells from ATL patients and leukemic cell lines, especially HTLV-1-related cell lines (S1T and MT-2). Sirtinol-induced apoptosis was mediated by activation of the caspase family, and inactivation of NF-kB, reducing IkBa phosphorylation. These results suggest that SIRT1 is a crucial antiapoptotic molecule in ATL cells, and that SIRT1 inhibitors may be useful therapeutic agents for leukemia, especially in patients with ATL. 61) CONCLUSION ATL is important with regard to studies of both the host immune system in chronic infection and virus-induced malignancy in humans. During the past 3 decades since the clinical discovery of ATL, the results of conventional cytotoxic chemotherapy remain dismal because of low response rates and lack of longterm e‹cacy. Experimental therapeutics for ATL is now under investigation using hematopoietic stem cell transplantation and molecular targeting by CCR4 antibody. Besides these treatments, the study targeted for anti-tumor immunity such as vaccine and a longevity gene-encoded protein such as SIRT1 may support the new prophylactic and therapeutic approach for ATL (Fig. 6) .
